Articles published by AIM ImmunoTech Inc.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

June 12, 2023

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

May 15, 2023

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

May 09, 2023

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

April 12, 2023

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

April 04, 2023

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

April 03, 2023

AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

March 30, 2023

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

March 27, 2023

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

March 16, 2023

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

March 08, 2023

AIM ImmunoTech Issues Letter to Stockholders

March 06, 2023

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

February 28, 2023

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

February 17, 2023

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

January 17, 2023

AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

January 09, 2023

AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’

January 05, 2023

AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

December 12, 2022

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

December 08, 2022

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

December 02, 2022

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 15, 2022

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

November 14, 2022

AIM ImmunoTech Announces Corporate Governance Enhancements

November 09, 2022

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

Tickers AIM

November 03, 2022

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Tickers AIM

November 02, 2022

Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid

October 31, 2022

Tickers AIM

AIM ImmunoTech Board Issues Letter to Shareholders

October 26, 2022

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Tickers AIM

October 12, 2022

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

September 19, 2022

Tickers AIM

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

August 15, 2022